CytoDyn Inc. (OTCQB:CYDY) recently announced the clinical trial results of its monoclonal antibody, leronlimab, in treating severe to critically ill patients with COVID-19. A deeper look at the data shows how important age was as
A New Look At CytoDyn's Severe-To-Critical COVID-19 Trial
Summary
- Trial data is supportive of an EUA: Leronlimab outperformed every approved or recommended drug in critically ill patients.
- Shorts have a flawed analysis that doesn’t correct for patient age distribution.
- The clinical outcome of length of hospitalization was statistically significant (p=.005).
- Dexamethasone is recommended as a standard of care based on age-adjusted meta-analysis data.
Investor, mechanical engineer
Analyst’s Disclosure:I am/we are long CYDY. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.